Logo Image
Opinion|Videos|January 31, 2025

The Inflation Reduction Act and Cost Considerations for BTK Inhibitors

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing the sequencing of Bruton tyrosine kinase (BTK) inhibitors in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treatment while considering other financial factors like insurance coverage, copays, and total out-of-pocket costs that impact patient access and treatment decisions.

Episodes in this series

Video content above is prompted by the following:

  • With ibrutinib on the negotiated drug price list under the IRA, how might cost considerations influence first-line BTK inhibitor selection and subsequently shape second-line and beyond treatment choices in R/R CLL?
  • Beyond the IRA, what role do broader economic factors, such as insurance coverage and out-of-pocket costs, play in treatment selection for patients with R/R CLL requiring BTK inhibitors?

Related Content